Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CRYSTODIGIN vs LANOXIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Cardiac glycoside that inhibits the Na+/K+-ATPase pump, leading to increased intracellular sodium, which in turn promotes calcium influx via the Na+/Ca2+ exchanger, resulting in increased myocardial contractility (positive inotropy). It also has negative chronotropic and dromotropic effects via vagomimetic action.
Inhibits Na+/K+ ATPase, increasing intracellular Ca2+ via Na+/Ca2+ exchange, enhancing cardiac contractility and reducing conduction through AV node.
Treatment of heart failure with reduced ejection fraction (FDA-approved),Control of ventricular response in atrial fibrillation and atrial flutter (FDA-approved)
Heart failure (NYHA class II-IV) with reduced ejection fraction,Atrial fibrillation and atrial flutter for rate control (off-label: paroxysmal supraventricular tachycardia)
0.5 mg intravenously over 2-4 hours, then 0.25 mg every 6 hours as needed up to a total of 1.5 mg in 24 hours.
0.125-0.25 mg orally once daily; loading dose 0.5-0.75 mg orally divided over 24-48 hours if rapid digitalization required.
Terminal elimination half-life approximately 1.6–1.9 days (38–45 hours) in patients with normal renal function; prolonged in renal impairment.
Terminal elimination half-life is approximately 36-48 hours in patients with normal renal function; prolonged to 3.5-5 days in anuria.
Primarily renal excretion; minimal hepatic metabolism. Not significantly metabolized by cytochrome P450 enzymes.
Primarily hepatic via CYP3A4 and renal excretion of unchanged drug; undergoes biliary excretion and enterohepatic recirculation.
Primarily renal excretion of unchanged drug; ~80-90% eliminated in urine, ~10-20% in feces via biliary excretion.
Renal excretion of unchanged drug (60-80%) and biliary/fecal elimination (20-40%).
~20–25% bound to plasma proteins, primarily albumin.
25-30% bound primarily to albumin.
Vd approximately 5–10 L/kg, indicating extensive tissue distribution; clinical significance: large Vd means low plasma concentration relative to total body load, necessitating loading doses.
Vd approximately 6-7 L/kg; indicates extensive tissue binding, particularly to cardiac muscle.
Oral: 60–80% (variable, depends on formulation and gastrointestinal factors); Intravenous: 100%.
Oral: 60-80%; Intravenous: 100%.
Cr Cl 10-50 m L/min: reduce dose by 25-50%; Cr Cl <10 m L/min: reduce dose by 50-75% or use alternative.
GFR >50 m L/min: no adjustment; GFR 10-50 m L/min: reduce dose by 50% or use 0.125 mg every 48 hours; GFR <10 m L/min: reduce dose by 75% or use 0.0625 mg daily; monitor digoxin levels.
Child-Pugh class B: reduce dose by 50%; Child-Pugh class C: avoid use.
No specific Child-Pugh based dose adjustment; use caution in severe hepatic impairment due to potential toxicity; monitor levels.
Loading dose: 10-20 mcg/kg intravenously over 2-4 hours; maintenance: 5-10 mcg/kg every 6 hours as needed.
Loading dose: 10-15 mcg/kg orally divided every 8 hours over 24 hours; maintenance: 5-10 mcg/kg/day orally in 2 divided doses; maximum 0.25 mg/day.
Start at lower end of dosing range (0.25 mg intravenously), adjust based on renal function and response, monitor for toxicity.
Start with 0.0625-0.125 mg orally daily; adjust based on renal function and drug levels; due to decreased lean body mass and renal clearance.
None.
None; however, toxicity is common and potentially fatal. Not a formal black box warning due to age of drug.
Narrow therapeutic index; toxicity can be life-threatening.,Hypokalemia, hypomagnesemia, and hypercalcemia increase risk of digoxin toxicity.,Electrolyte monitoring and dose adjustment in renal impairment.,Patients with acute myocardial infarction, myocarditis, or severe pulmonary disease may be at increased risk of arrhythmias.
Toxicity risk: hypokalemia, hypomagnesemia, hypercalcemia increase sensitivity,Renal impairment requires dose adjustment,Digoxin immune Fab for life-threatening overdose,Pregnancy category C,Monitor serum levels and ECG
Ventricular fibrillation,Known hypersensitivity to digoxin or other digitalis glycosides,Hypercalcemia,Hypokalemia (uncorrected),Atrioventricular block (second- or third-degree) unless a pacemaker is present,Hypertrophic obstructive cardiomyopathy (relative contraindication)
Hypersensitivity,Ventricular fibrillation,AV block (unless pacemaker present),Wolff-Parkinson-White syndrome with atrial fibrillation,Hypertrophic obstructive cardiomyopathy,Hypokalemia or hypercalcemia (relative)
Avoid high-fiber foods and large amounts of bran or pectin, as they may reduce absorption. Grapefruit juice may increase blood levels; limit consumption. Consistent dietary potassium intake is important; extremes (high or low) can affect drug action.
High-fiber foods (bran) may decrease absorption; take digoxin 2 hours before or after high-fiber meals. Potassium-rich foods (bananas, oranges, spinach) can affect toxicity risk; maintain consistent intake. Avoid excessive licorice (glycyrrhizin can cause hypokalemia). Grapefruit juice may increase digoxin absorption; avoid large amounts.
Pregnancy Category C. First trimester: Association with fetal cardiac glycoside toxicity and malformations in animal studies; limited human data. Second trimester: Potential for fetal bradycardia and hypoxia due to placental transfer. Third trimester: Risk of neonatal digitalis toxicity, including arrhythmias and heart block.
Digoxin crosses the placenta. First trimester: No increased risk of major malformations reported in human studies; animal studies show no teratogenicity at clinically relevant doses. Second/third trimester: Risk of fetal toxicity (bradycardia, arrhythmias) if maternal serum levels are supratherapeutic; therapeutic maternal levels are generally safe. Chronic use may be associated with reduced birth weight.
Excreted in breast milk in low concentrations (M/P ratio approximately 0.75-1.0). Considered compatible with breastfeeding; monitor infant for signs of toxicity (bradycardia, vomiting).
Digoxin is excreted into breast milk in low concentrations. M/P ratio approximately 0.6–0.9. At typical maternal doses (0.125–0.5 mg/day), the estimated infant dose is less than 10% of the weight-adjusted neonatal maintenance dose, usually considered compatible with breastfeeding. Monitor infant for signs of digoxin toxicity (bradycardia, poor feeding, vomiting).
Increased volume of distribution and renal clearance in second and third trimesters may necessitate dose increases. Monitor serum digoxin levels and adjust to maintain therapeutic range (0.5-1.0 ng/m L).
Pregnancy increases glomerular filtration rate (GFR) and volume of distribution, which may lower serum digoxin concentrations; dose adjustments are often needed. Monitor serum levels and adjust dose to maintain therapeutic range (0.5–2.0 ng/m L). Consider increasing dose by 30-50% in later pregnancy if levels are low; postpartum dose may need reduction to prepregnancy levels.
Crystodigin (digitoxin) has a very long half-life (~5-7 days) requiring careful monitoring to avoid accumulation. Unlike digoxin, it is primarily hepatically metabolized, so renal impairment has less impact on dosing. Always check for drug interactions with CYP3A4 inducers/inhibitors. Therapeutic monitoring of serum levels is essential (target 15-25 ng/m L).
Check serum digoxin level 6-8 hours after last dose; therapeutic range 0.5-2.0 ng/m L. Hypokalemia, hypomagnesemia, hypercalcemia increase toxicity risk. Use with caution in renal impairment (reduce dose). Monitor for bradycardia and arrhythmias. Avoid in patients with AV block (except pacemaker) or hypertrophic cardiomyopathy. Loading dose: 10-15 mcg/kg lean body weight. Maintenance: 0.125-0.25 mg daily. Consider drug interactions with amiodarone, verapamil, quinidine, and macrolides.
Take exactly as prescribed; do not miss doses or double up.,Report any symptoms of toxicity: nausea, vomiting, visual disturbances (yellow-green halos), or irregular heartbeat.,Avoid over-the-counter medications without consulting your doctor, especially antacids and laxatives.,Keep regular appointments for blood tests to monitor drug levels and kidney function.,Do not stop suddenly; withdrawal can worsen heart condition.
Take digoxin exactly as prescribed, usually once daily. Do not miss doses or double up.,Monitor pulse before each dose; hold and contact prescriber if heart rate <60 bpm.,Report symptoms of toxicity: nausea, vomiting, diarrhea, blurred vision, yellow-green halos, confusion, or irregular heartbeat.,Avoid over-the-counter antacids, laxatives, or kaolin-pectin; they reduce absorption. Take digoxin 2 hours apart from such products.,Maintain consistent intake of potassium-rich foods (bananas, oranges) unless otherwise instructed. Avoid excessive salt substitutes.,Keep all appointments for blood tests (digoxin levels, potassium, kidney function).,Store at room temperature away from light and moisture.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CRYSTODIGIN vs LANOXIN, answered by our medical review team.
CRYSTODIGIN is a Cardiac Glycoside that works by Cardiac glycoside that inhibits the Na+/K+-ATPase pump, leading to increased intracellular sodium, which in turn promotes calcium influx via the Na+/Ca2+ exchanger, resulting in increased myocardial contractility (positive inotropy). It also has negative chronotropic and dromotropic effects via vagomimetic action.. LANOXIN is a Cardiac Glycoside that works by Inhibits Na+/K+ ATPase, increasing intracellular Ca2+ via Na+/Ca2+ exchange, enhancing cardiac contractility and reducing conduction through AV node.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CRYSTODIGIN and LANOXIN depend on the specific clinical indication. These are both Cardiac Glycoside agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CRYSTODIGIN is: 0.5 mg intravenously over 2-4 hours, then 0.25 mg every 6 hours as needed up to a total of 1.5 mg in 24 hours.. The standard adult dose of LANOXIN is: 0.125-0.25 mg orally once daily; loading dose 0.5-0.75 mg orally divided over 24-48 hours if rapid digitalization required.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CRYSTODIGIN and LANOXIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CRYSTODIGIN is classified as Category C. Pregnancy Category C. First trimester: Association with fetal cardiac glycoside toxicity and malformations in animal studies; limited human data. Second trimester: Potential for fe. LANOXIN is classified as Category C. Digoxin crosses the placenta. First trimester: No increased risk of major malformations reported in human studies; animal studies show no teratogenicity at clinically relevant dose. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.